Investment Rating - The report maintains an "Outperform" rating for Zai Lab with a target price of HKD 35.25, indicating an expected return exceeding the market benchmark over the next 12-18 months [2][19]. Core Insights - Zai Lab is projected to achieve product net revenue of USD 465 million in FY25, representing a year-on-year growth of 16.5%. The core product, efgartigimod, is expected to generate USD 97.96 million, with a gross profit margin of 61.0% [3][16]. - The management emphasizes a dual-engine strategy focusing on introducing high-quality overseas products for commercialization in China and leveraging a cross-border R&D platform for efficient global market development [4][17]. - Despite a downward revision in revenue guidance for 2025 and a delay in profitability targets, the company has a robust portfolio with eight products approved in China and several differentiated global assets in its pipeline [4][17]. Financial Performance - Revenue forecasts for FY25-FY27 have been adjusted to USD 465 million, USD 501 million, and USD 717 million, respectively. Net loss estimates for the same period are revised to USD 180 million, USD 159 million, and USD 55 million [10][19]. - R&D expenses are expected to be USD 205 million, a decrease of 12.8% year-on-year, while SG&A expenses are projected at USD 284 million, down 5.0% [3][16]. Clinical Development Pipeline - Zocilurtatug (DLL3 ADC) is set to initiate three registrational clinical trials by the end of 2026, targeting small cell lung cancer and neuroendocrine carcinoma [5][21]. - Several early-stage products, including ZL-1503 for atopic dermatitis and ZL-6201 for various solid tumors, are anticipated to contribute to long-term global value [6][9][21].

上 市 公 司 报告原因：有业绩公布需要点评 增持（维持） | 市场数据： | 2026 年 01 月 28 日 | | --- | --- | | 收盘价（港币） | 22.10 | | 恒生中国企业指数 | 9512.24 | | 52 周最高/最低（港币） | 53.70/10.12 | | H 股市值（亿港币） | 232.89 | | 流通 H 股（百万股） | 1,053.81 | | 汇率（港币/人民币） | 0.8943 | 一年内股价与基准指数对比走势： 2026 年 01 月 29 日 东方甄选 (01797) ——产品组合优化，经营效益大幅提升 公 司 研 究 / 公 司 点 评 社会服务 -37% 63% 163% 263% 01/28 02/28 03/31 04/30 05/31 06/30 07/31 08/31 09/30 10/31 11/30 12/31 HSCEI 东方甄选 资料来源：Bloomberg 相关研究 - 证券分析师 黄哲 A0230513030001 huangzhe@swsresearch.com 联系人 投资要点： 东方甄选 1HFY26（2025 年 ...

Investment Rating - The report assigns a "Buy" rating for the company, Hesai Technology (2525.HK), indicating a positive outlook for its stock performance [6]. Core Insights - The company is projected to achieve total revenues of 3.1 billion, 4.8 billion, and 6.1 billion yuan from 2025 to 2027, with net profits of 370 million, 690 million, and 1.09 billion yuan respectively. As a global leader in LiDAR technology, Hesai is expected to rapidly expand in high-level autonomous driving and robotics sectors [1][6]. - The market perception is that the LiDAR space is limited; however, the report argues that there is significant potential, particularly in the automotive sector, where over 100,000 models are expected to adopt LiDAR technology. The report anticipates an increase in the number of LiDAR units per vehicle and an enhancement in average selling price (ASP) as autonomous driving technology evolves [1][14]. Summary by Sections Company Overview - Hesai Technology is recognized as a global leader in LiDAR development and manufacturing, with products widely used in advanced driver-assistance systems (ADAS), autonomous vehicles, and various robotic applications [19][40]. - The company has established a comprehensive product matrix covering multiple scenarios, including ADAS, robotics, and high-precision modeling [19]. Strategic Advantages - The founders of Hesai have clearly defined roles that complement each other, contributing to the company's strategic foresight and technological leadership. The company was an early entrant into the L4 market and has maintained a focus on chip-based LiDAR and mirror technology [2]. - Hesai's research and development capabilities are industry-leading, having introduced the chip-based approach early on. The AT128 LiDAR, launched in 2022, was the first chip-based long-range LiDAR product to achieve automotive-grade mass production [2]. - The proprietary manufacturing processes of Hesai integrate R&D and design, ensuring high performance, reliability, and cost-effectiveness. The company plans to increase its production capacity to 4 million units by 2026 [2]. Financial Projections - Revenue projections for 2023 to 2027 indicate significant growth, with expected revenues of 1.88 billion, 2.08 billion, 3.07 billion, 4.77 billion, and 6.11 billion yuan respectively. The net profit is expected to turn positive by 2025, reaching 367 million yuan [4][13]. - The report highlights a projected compound annual growth rate (CAGR) of 48% from 2025 to 2027, with a focus on expanding customer bases in both domestic and international markets [16]. Market Position and Competitive Landscape - Hesai has secured partnerships with over 22 major OEMs, covering more than 120 vehicle models, including prominent Chinese brands. The company is also expanding its international presence, collaborating with leading Tier 1 suppliers in Japan and Europe [27][28]. - The report emphasizes that Hesai's technology, particularly in SPAD and IPE, positions it well against competitors, enabling it to maintain a competitive edge in the rapidly evolving LiDAR market [32]. Product Development and Innovation - The company has developed a diverse range of LiDAR products tailored for various applications, including the ET, AT, FT, JT, and XT series, each designed to meet specific market needs from L2 to L4 autonomous driving [21][24]. - The introduction of the "Thousand Eye" LiDAR solution, which combines multiple LiDAR units for comprehensive coverage, showcases Hesai's commitment to innovation and market leadership [26].

Investment Rating - The report maintains a "Buy" rating for the company, anticipating continued growth in its multi-brand strategy [4]. Core Insights - The acquisition of approximately 29.06% of PUMA for €35 per share, totaling around €1.506 billion (approximately RMB 12.28 billion), positions the company as PUMA's largest shareholder, enhancing its "single focus, multi-brand, globalization" strategy [2][3]. - The acquisition aims to leverage PUMA's global influence in professional sports sectors such as football, running, and esports, addressing the company's current weaknesses in these areas while enhancing its international competitiveness [3]. - The company plans to provide strategic support to PUMA while respecting its brand independence, aiming for long-term value creation through collaboration [3]. Financial Projections - Expected EPS for 2025-2027 is projected at RMB 4.74, RMB 5.06, and RMB 5.70, with corresponding P/E ratios of 15, 14, and 13 times [4]. - Revenue forecasts for 2025-2027 are RMB 78.35 billion, RMB 86.37 billion, and RMB 94.99 billion, with growth rates of 10.62%, 10.24%, and 9.97% respectively [9]. - The net profit for 2025-2027 is estimated at RMB 13.25 billion, RMB 14.14 billion, and RMB 15.94 billion, with growth rates of -15.02%, 6.70%, and 12.75% respectively [9].

Investment Rating - The report maintains a "Buy" rating for the company [2] Core Insights - The company is transitioning from a high-end offline maternity service provider to a comprehensive maternal and infant health service platform driven by AI technology [4][5] - The "Bela Doctor" app serves as the core entry point for a full-cycle service ecosystem, integrating external AI capabilities and internal professional service systems [6] - The company has established a scientific "age-based parenting" service system, enhancing customer experience and brand loyalty [7] - Strategic investment in AI service provider WITH1000 AI aims to improve user understanding and industry standards [8] - Collaboration with China Merchants Bank to create a secure maternity guarantee fund account enhances customer confidence [9] Financial Projections - Revenue forecasts for 2025-2027 are projected at 1.076 billion, 1.403 billion, and 1.777 billion yuan, representing year-on-year growth of 34.73%, 30.42%, and 26.65% respectively [11] - Net profit forecasts for the same period are 315 million, 406 million, and 478 million yuan, with growth rates of 157.65%, 28.75%, and 17.71% respectively [11] - The company is expected to achieve an EPS of 0.51, 0.65, and 0.77 yuan for 2025, 2026, and 2027 [13]

业绩表现超预期，定价首饰占比提升强化盈利韧性 [Table_Title] 【广发批零社服&海外】周大福 （01929.HK） [Table_Summary] 核心观点： 盈利预测： | [Table_ 单位Finance] :港元百万元 | | 2024A | 2025A | 2026E | 2027E | 2028E | | --- | --- | --- | --- | --- | --- | --- | | 主营收入 | | 108,713 | 89,656 | 94,150 | 101,463 | 108,211 | | 增长率（ ） | % | 14.8% | -17.5% | 5.0% | 7.8% | 6.7% | | EBITDA | | 11,535 | 10,499 | 13,212 | 15,441 | 16,688 | | 归母净利润 | | 6,499 | 5,916 | 8,161 | 9,803 | 10,716 | | 增长率（ ） | % | 20.7% | -9.0% | 38.0% | 20.1% | 9.3% | | EPS（元/股） | | 0.65 | 0.59 | ...

证券研究报告：食品饮料 | 公司点评报告 发布时间：2026-01-29 研究所 分析师:蔡雪昱 SAC 登记编号:S1340522070001 Email:caixueyu@cnpsec.com 分析师:杨逸文 SAC 登记编号:S1340522120002 Email:yangyiwen@cnpsec.com 圣贝拉 (2508.HK) 以 AI+服务为核心，全面升级母婴护理生态 ⚫ 事件 公司近期围绕"家庭大健康生态战略"进行一系列系统化、多维度 的能力升级，从一家高端线下月子服务商，加速向一个以 AI 技术为 引擎、专业体系为基石、金融级信任为护城河的母婴健康综合服务平 台演进。 股票投资评级 买入|维持 公司基本情况 | 最新收盘价（港元） | 4.69 | | --- | --- | | 总股本/流通股本（亿股）6.22 / 6.22 | | | 总市值/流通市值（亿港 | 29.37/ 29.37 | | 元） | | | 52 周内最高/最低价 | 11.00/3.40 | | 资产负债率(%) | 36.35% | | 市盈率 | -5.04 | | 第一大股东 | 向华 | ⚫ 投资要点 ...

對外方面，集團作為獨立第三方及具備全場景業務覆蓋能力的平台， 可承接全渠道訂單，包括抖音、淘寶閃購、京東秒送等。阿里早前提 出，2026 年淘寶閃購首要目標是份額增長，相信順豐同城將受惠於其 加快擴張及份額爭奪。此外，隨著需求場景拓闊至非餐飲實物以及生 活服務領域，相關領域的商家並未與現有平台建立綁定關係，為獨立 第三方即時配送平台帶來增長動力。在需求強勁的背景下，集團有望 優先匹配新增需求。 個股推介 順豐同城(9699.HK) 2026 年 1 月 29 日星期四 實行配送場景全覆蓋，受惠即時零售市場持續擴張 2024 年內地即時零售規模達 7,810 億元人民幣，商務部預期 2025 年 將達 9,714 億元人民幣，至 2030 年將達到 2 萬億元人民幣，「十五 五」期間年均增速將達 12.6%。順豐同城是內地最大的第三方即時配 送平台，擁有強大的品牌效應和行業影響力。集團已全方位覆蓋餐飲 外賣、同城零售及近場電商，形成強大的市場布局，料將受惠於即時 零售市場持續擴張。 節日期間提供穩定履約保障，突顯其即時配送能力 順豐同城數據顯示，2026 年元旦假期期間，同城配送日均單量按年增 長 55%，其中 ...

证券研究报告 交通运输 | 航运港口 港股|公司点评报告 hyzqdatemark 2026 年 01 月 29 日 证券分析师 孙延 SAC：S1350524050003 sunyan01@huayuanstock.com 曾智星 SAC：S1350524120008 zengzhixing@huayuanstock.com 王惠武 SAC：S1350524060001 wanghuiwu@huayuanstock.com 张付哲 SAC：S1350525070001 zhangfuzhe@huayuanstock.com 33.00/15.70 风险提示。美国关税政策变化；经济增长不及预期；红海复航；美国对航运港口相 关政策的变化；地缘政治风险。 | 资产负债率（%） | 22.55 | 盈利预测与估值（美元） | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 资料来源：聚源数据 | | | 2023 | 2024 | 2025E | 2026E | 2027E | | | | 营业收入（百万美元） | 2,429 | 3,05 ...

Investment Rating - The investment rating for China Tobacco Hong Kong (6055.HK) is not explicitly stated in the provided documents, but the report indicates a positive outlook based on recent developments and financial projections [1]. Core Insights - The company has signed a framework agreement with Leaf Trading, increasing the annual trading limit for tobacco sales to HKD 6.7 million, HKD 8.4 million, and HKD 9.8 million for the years 2026 to 2028 respectively [1]. - A framework agreement has also been established with China Tobacco International (North America) for the export of tobacco leaves to new regions, with the annual trading limits raised significantly for 2026 and 2027, reflecting increases of 538.4% and 456.8% respectively [1][2]. - The adjustments in trading limits are based on past orders, current orders, expected demand, and the company's business expansion, indicating strong confidence in future business growth [2]. - The company aims to diversify its customer base and attract potential buyers from broader regions, particularly in Southeast Asia [2]. Financial Summary - The company’s total revenue is projected to grow from HKD 13,074 million in 2024 to HKD 18,823 million in 2027, with year-on-year growth rates of 10%, 16%, 12%, and 11% respectively [4]. - The net profit attributable to the parent company is expected to increase from HKD 854 million in 2024 to HKD 1,310 million in 2027, with growth rates of 43%, 19%, 16%, and 11% respectively [4]. - Earnings per share (EPS) is forecasted to rise from HKD 1.23 in 2024 to HKD 1.89 in 2027 [4]. - The company is positioned as the exclusive operational entity for international business expansion and related trade for China Tobacco International, with a strong potential for mergers and acquisitions to accelerate growth [3]. Operational Performance - In the first half of 2025, the company reported tobacco leaf import/export revenues of HKD 839.9 million and HKD 115.6 million, representing year-on-year increases of 23.5% and 25.9% respectively [2]. - The company’s cigarette export revenue was HKD 115.6 million, showing a slight increase of 0.8%, while new tobacco products experienced a significant decline of 66.5% [2]. - The Brazilian operations reported a revenue of HKD 19.5 million, down 50.3% year-on-year, indicating some operational challenges [2].